Mohamed, Abdellatif OuldRostaing, LionelDuffas, Jean PierreEsposito, LaureNogier, Marie-BéatriceKamar, Nassim2025-12-092009-09Experimental and Clinical Transplantation, Cilt, 7, Sayı, 3, 2009 ss. 164-1671304-0855https://hdl.handle.net/11727/14094Objectives: Encapsulating peritoneal sclerosis is a rare but serious complication in patients undergoing peritoneal dialysis. Its mortality rate is approximately 30%, despite treatment with total parenteral nutrition, surgery, tamoxifen, or immunosuppressants. Materials and Methods: Of 991 kidney transplants performed at our institution over 9 years, 50 patients were treated for chronic peritoneal dialysis at the time of transplant. Results: Two cases of encapsulating, peritoneal sclerosis occurred in patients receiving pretransplant peritoneal dialysis. Both had received intensive posttransplant treatment for acute humoral rejection. Encapsulating peritoneal sclerosis occurred at 3 months and 4 months after the transplant. Both presented with intestinal pain and gut obstruction. They were given total parenteral nutrition plus tamoxifen (20 mg/d) for 3 months. Outcomes were favorable for 1, though there was no improvement for the second patient, who was then also given sirolimus. He died later from multiorgan failure secondary to digestive-related sepsis, and encapsulating, peritoneal, sclerosis-related symptoms. Conclusions: When encapsulating, peritoneal sclerosis occurs after kidney transplant, tamoxifen therapy could be implemented.en-USTotal parenteral nutritionContinuous ambulatory peritoneal dialysisDialysisImmuno-suppressantsArticle732146-8427